Fully defined NGN2 neuron protocol reveals diverse signatures of neuronal maturation
NGN2-driven induced pluripotent stem cell (iPSC)-to-neuron conversion is a popular method for human neurological disease modeling. In this study, we present a standardized approach for generating neurons utilizing clonal, targeted-engineered iPSC lines with defined reagents. We demonstrate consistent production of excitatory neurons at scale and long-term maintenance for at least 150 days. Temporal omics, electrophysiological, and morphological profiling indicate continued maturation to postnatal-like neurons. Quantitative characterizations through transcriptomic, imaging, and functional assays reveal coordinated actions of multiple pathways that drive neuronal maturation. We also show the expression of disease-related genes in these neurons to demonstrate the relevance of our protocol for modeling neurological disorders. Finally, we demonstrate efficient generation of NGN2-integrated iPSC lines. These workflows, profiling data, and functional characterizations enable the development of reproducible human in vitro models of neurological disorders.
Authors
- Meena Choi (ORCID: https://orcid.org/0000-0002-6025-5035)
- Carlos Sánchez-Priego
- Mitchell G. Rezzonico
- Ming‐Chi Tsai (ORCID: https://orcid.org/0000-0002-6216-8672)
- Casper C. Hoogenraad (ORCID: https://orcid.org/0000-0002-2666-0758)
- Christopher M. Rose (ORCID: https://orcid.org/0000-0002-7502-3368)
- Yingjie Zhang (ORCID: https://orcid.org/0000-0003-0745-2563)
- Michelle B. Chen
- Xiwei Shan
- Jillian M. Pattison
- Qiao Zhang (ORCID: https://orcid.org/0000-0001-9682-3295)
- Ai Zhang (ORCID: https://orcid.org/0000-0002-5122-4296)
- Amber Cramer
- José Miguel Andrade López
- Lilian Phu
- Claire G. Jeong
Institutions
- Gene Therapy Laboratory (FR)
- Advanced Pharma (US)
- Genomic Health (United States) (US)
Publication Details
- Journal
- Cell Reports Methods
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.crmeth.2024.100858
- Citations
- 26
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 6.08
Funders
- Genentech